Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes - Takeaways - MDSpire

Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes

  • By

  • Wancheng Guo

  • Wenhe Li

  • Xianlin Li

  • Wen Shi

  • Yan Yan

  • Ting Yan

  • Jie Zhou

  • Yujie Huang

  • June 3, 2026

  • 0 min

Share

  • 1

    SGLT2 inhibitors (SGLT2is) significantly reduced ALT and AST levels more than GLP-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes and NAFLD.

  • 2

    The study involved 705 subjects with type 2 diabetes and NAFLD, comparing the effects of SGLT2is and GLP-1RAs over six months.

  • 3

    After matching, SGLT2is showed greater reductions in ALT (ΔALT: -10.55 U/L) and AST (ΔAST: -7.68 U/L) compared to GLP-1RAs.

  • 4

    Weight change was linked to AST reduction but not to ALT reduction, indicating SGLT2is may have direct hepatoprotective effects.

  • 5

    The findings suggest SGLT2is may be preferred for improving liver function in patients with type 2 diabetes and NAFLD.

Original Source(s)

Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes

  • by Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang

  • June 3, 2026

Related Content

Impact of incision type in breast cancer-conserving mastectomy: a comparative analysis of outcome

Cardiovascular–kidney–metabolic syndrome and mortality in a prospective UK cohort study

Special Series eBook: GLP-1 Analysis

Experts explore how analytical science is meeting the challenges shaping GLP-1 therapeutics

  • April 14, 2026

  • 1 min